Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2,930 MXN
Change Today 0.00 / 0.00%
Volume 0.0
ILMN* On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:09 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN*) Snapshot

Open
$2,930
Previous Close
$2,930
Day High
$2,930
Day Low
$2,930
52 Week High
04/21/15 - $3,100
52 Week Low
05/20/14 - $1,940
Market Cap
422.2B
Average Volume 10 Days
1.5K
EPS TTM
--
Shares Outstanding
144.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN*)

illumina inc (ILMN*) Details

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology, which provides researchers with various ranges of applications and the ability to sequence mammalian genomes; and array platforms consist of HiScan and iScan systems, as well as NextSeq 550 system that are array scanners for DNA and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis. It also offers various library preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping, noninvasive prenatal test, and whole-genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has a collaboration agreement with Merck Serono to develop a sequencing-based oncology diagnostic. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,700 Employees
Last Reported Date: 02/18/15
Founded in 1998

illumina inc (ILMN*) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $859.2K
President and Director
Total Annual Compensation: $689.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $463.3K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $467.5K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $403.7K
Compensation as of Fiscal Year 2014.

illumina inc (ILMN*) Key Developments

Cloud Health Medical Group Ltd Selects Illumina, Inc. for its HiSeq X Ten System

Cloud Health Medical Group Ltd. has selected Illumina Inc. for its HiSeq X Ten System, a whole-genome sequencing platform. Cloud Health Medical has launched the full service capacity of the most powerful human whole-genome sequencing platform. This will enable Cloud Health to promote the application of genetic sequencing technologies for both public health and clinical research within China. With the HiSeq X Ten, Cloud Health will conduct advanced exploration of the human genome to better understand the body's genetic background, as well as individual health and well-being.

Illumina Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 29, 2015; Revises Earnings Guidance for the Year 2015

Illumina Inc. reported unaudited consolidated earnings results for the first quarter ended March 29, 2015. For the quarter, the company reported revenue of $539 million, a 28% increase compared to $421 million in the first quarter of 2014, and an increase of 33% on a constant currency basis. GAAP net income for the quarter was $137 million, or $0.92 per diluted share, compared to $60 million, or $0.40 per diluted share, for the first quarter of 2014. Non-GAAP net income for the quarter was $135 million, or $0.91 per diluted share, compared to $80 million, or $0.53 per diluted share, for the first quarter of 2014. Income from operations was $176,126,000 compared to $92,096,000 a year ago. Income before income taxes was $178,046,000 compared to $83,788,000 a year ago. Net cash provided by operating activities was $66,779,000 compared to $37,087,000 a year ago. Free cash flow was $30,228,000 compared to $18,075,000 a year ago. Purchases of property and equipment were $36,551,000 compared to $19,012,000 a year ago. Non-GAAP operating profit was $211,743,000 compared to $146,979,000 a year ago. In the first quarter the company delivered significant earnings growth as a result of strong demand for products across sequencing portfolio. For fiscal 2015, the company continues to project approximately 20% total revenue growth, which now includes a 3% negative impact from foreign exchange assuming current currency exchange rates. The company has increased its projections for non-GAAP earnings per diluted share to $3.36 to $3.42 up from $3.12 to $3.18. These projections assume a pro forma tax rate of approximately 27%. GAAP diluted net income per share is expected to be in the range of $3.07 to $3.13.

Illumina Inc. to Report Q1, 2015 Results on Apr 21, 2015

Illumina Inc. announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on Apr 21, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN*:MM $2,930.00 MXN 0.00

ILMN* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $122.80 USD +5.92
Dr Reddy's Laboratories Ltd 3,395 INR +84.80
Hologic Inc $34.01 USD +0.265
Sigma-Aldrich Corp $138.94 USD +0.02
Waters Corp $126.59 USD +1.40
View Industry Companies
 

Industry Analysis

ILMN*

Industry Average

Valuation ILMN* Industry Range
Price/Earnings 66.0x
Price/Sales 13.9x
Price/Book 16.9x
Price/Cash Flow 58.4x
TEV/Sales 12.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.